213 related articles for article (PubMed ID: 23962561)
1. Application of the concept synthetic lethality toward anticancer therapy: a promise fulfilled?
Canaani D
Cancer Lett; 2014 Sep; 352(1):59-65. PubMed ID: 23962561
[TBL] [Abstract][Full Text] [Related]
2. [Synthetic lethality as a functional tool in basic research and in anticancer therapy].
Toma M; Skorski T; Sliwiński T
Postepy Hig Med Dosw (Online); 2014 Sep; 68():1091-103. PubMed ID: 25228518
[TBL] [Abstract][Full Text] [Related]
3. Methodological approaches in application of synthetic lethality screening towards anticancer therapy.
Canaani D
Br J Cancer; 2009 Apr; 100(8):1213-8. PubMed ID: 19319136
[TBL] [Abstract][Full Text] [Related]
4. The concept of synthetic lethality in the context of anticancer therapy.
Kaelin WG
Nat Rev Cancer; 2005 Sep; 5(9):689-98. PubMed ID: 16110319
[TBL] [Abstract][Full Text] [Related]
5. Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.
Kacsinta AD; Dowdy SF
Expert Opin Biol Ther; 2016; 16(2):161-72. PubMed ID: 26630128
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Xia Y; Choi HK; Lee K
Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
[TBL] [Abstract][Full Text] [Related]
7. Synthetic lethal vulnerabilities of cancer.
Fece de la Cruz F; Gapp BV; Nijman SM
Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of CXC chemokines and their receptors in cancer.
Vinader V; Afarinkia K
Future Med Chem; 2012 May; 4(7):853-67. PubMed ID: 22571611
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibition as a prototype for synthetic lethal screens.
Liu X
Methods Mol Biol; 2013; 986():123-37. PubMed ID: 23436410
[TBL] [Abstract][Full Text] [Related]
10. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput siRNA screening platform to identify MYC-synthetic lethal genes as candidate therapeutic targets.
Grandori C
Methods Mol Biol; 2013; 1012():187-200. PubMed ID: 24006065
[TBL] [Abstract][Full Text] [Related]
12. siRNA and shRNA as anticancer agents in a cervical cancer model.
Gu W; Putral L; McMillan N
Methods Mol Biol; 2008; 442():159-72. PubMed ID: 18369785
[TBL] [Abstract][Full Text] [Related]
13. shRNA-mediated RNA interference as a tool for genetic synthetic lethality screening in mouse embryo fibroblasts.
Einav Y; Agami R; Canaani D
FEBS Lett; 2005 Jan; 579(1):199-202. PubMed ID: 15620713
[TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
15. Synthetic lethality as an engine for cancer drug target discovery.
Huang A; Garraway LA; Ashworth A; Weber B
Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic synthetic lethality approaches in cancer therapy.
Yang H; Cui W; Wang L
Clin Epigenetics; 2019 Oct; 11(1):136. PubMed ID: 31590683
[TBL] [Abstract][Full Text] [Related]
17. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
18. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
19. Exploration of synthetic lethal interactions as cancer drug targets.
Kuiken HJ; Beijersbergen RL
Future Oncol; 2010 Nov; 6(11):1789-802. PubMed ID: 21142664
[TBL] [Abstract][Full Text] [Related]
20. [Combinatorial RNAi and its application in cancer gene therapy].
Fei LN; Wang QZ; Xu RA
Yao Xue Xue Bao; 2012 May; 47(5):573-9. PubMed ID: 22811998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
